SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio today announced that Bryan Giraudo will join its executive management team as Chief Financial Officer. Mr. Giraudo comes to Gossamer Bio following a distinguished 20-plus-year career in investment banking where he focused exclusively in the life sciences and biotechnology sectors. Mr. Giraudo will lead the company’s finance and administrative functions.
“We are thrilled to welcome Bryan to the Gossamer team,” said Faheem Hasnain, Co-Founder, Chief Executive Officer and Chairman of Gossamer Bio. “His industry reputation and tremendous experience will no doubt be a valuable addition to our organization.”
“Bryan has an extensive and proven track record in our space,” said Sheila Gujrathi, Co-Founder, President and Chief Operating Officer of Gossamer Bio. “His contributions will be critical as we continue to execute on our bold vision of developing a portfolio of innovative, life-changing therapies.”
Mr. Giraudo was previously Senior Managing Director at LEERINK Partners, where he was responsible for LEERINK’s Western North America and Asia life sciences investment banking practice. Prior to joining LEERINK Partners in 2009, Bryan was a Managing Director in Merrill Lynch’s Global Healthcare Investment Banking Group. Bryan received his B.A. from Georgetown University.
“I am very excited to join Gossamer Bio at this crucial time in the company’s history,” said Mr. Giraudo. “I have long admired the team’s focus and vision on bringing transformational therapies to patients and I look forward to being part of Gossamer’s bright future and supporting its mission.”
About Gossamer Bio:
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.